Romics I, Dietmar B, Christoph R
St. Agnes Hospital, Urológiai Osztály, Bocholt, NSZK.
Orv Hetil. 1990 Jan 7;131(1):25-8.
The authors carried out immunotherapy in bladder cancer patients in stage pTa-1 G1-2 NoMo. The strain Connaught BCG (120 mg) was instilled weekly for 6 consecutive weeks in 26 patients. Another 13 patients were treated with 150 mg BCG strain Pasteur. The patients were followed average 26 months in the first, 16 months in the second group. The recurring of the tumor were found in 26% and 15% as well. Side effects were experienced more often in the third group. The authors advice the BCG therapy of the superficial bladder cancer.
作者对pTa-1 G1-2 NoMo期膀胱癌患者进行了免疫治疗。26例患者连续6周每周灌注120mg诺康BCG菌株。另外13例患者接受150mg巴斯德BCG菌株治疗。第一组患者平均随访26个月，第二组为16个月。肿瘤复发率分别为26%和15%。第三组患者出现副作用的情况更常见。作者建议对浅表性膀胱癌采用BCG治疗。
